Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

Condition:   Oral Cavity Squamous Cell Carcinoma
Intervention:   Drug: Nivolumab
Sponsors:   VU University Medical Center;   Bristol-Myers Squibb
Not yet recruiting

http://bit.ly/2GwAdNA